Directory

Directory

Lim Wan-Teck Darren

Professor, Centre for Clinician-Scientist Plus Development

Interim Director, Centre for Clinician-Scientist Plus Development

darren.lim@duke-nus.edu.sg

About

Academic Contributions

Professional

Research Interests

Publications

Bio

Dr Lim is a medical oncologist with clinical and research interests in lung cancer and cancers of the head and neck (in particular nasopharyngeal carcinoma). He completed training in Singapore, and research fellowship in thoracic oncology and drug development in Washington University in St Louis, USA.

He is currently a senior consultant in Division of Medical Oncology, National Cancer Centre Singapore, Professor at Duke-NUS Medical School, and a Senior Principal Investigator, IMCB, A*STAR.

His research focuses on clinical trials in nasopharyngeal carcinoma and lung cancer, incorporating correlative studies into the biology of resistance and immune response, and the development of circulating biomarkers.

Education

Bachelor of Medicine, Bachelor of Surgery

National University of Singapore, Singapore

NUS Appointment(s)

Clinical Senior Lecturer

YLLSOM, NUS, Currently Active

Academic Contribution(s)

National Day Long Service Award

Ministry of Health,2021

Clinician Scientist Award

National Medical Research Council,2017

Outstanding Clinician Researcher

SingHealth,2013

Clinician Scientist Award

National Medical Research Council,2012

Excellent Service Award (Gold)

SingHealth,2009

Excellent Service Award (Silver)

SingHealth,2008

Health Manpower Development Plan (HMDP) Award, SingHealth, 2004-2005

SingHealth,2005

Professional Appointment(s)

Senior Consultant, Division of Medical Oncology

National Cancer Centre Singapore, Currently Active

Director

Investigational Medicine Unit, SingHealth, 12/2010 - 10/2019

Regular/Associate Professor

Duke-NUS Medical School, Currently Active

Research Director, Division of Medical Oncology

National Cancer Centre Singapore, 10/2014 - 10/2020

Senior Principal Investigator

Institute of Molecular and Cell Biology, A*STAR, Currently Active

Research Director

SingHealth Duke-NUS Lung Disease Centre, Currently Active

Membership

Fellow

Academy of Medicine Singapore, Currently Active

Member

European Society of Medical Oncology, Currently Active

Member

Singapore Society of Oncology, Currently Active

Member

American Association for Cancer Research, Currently Active

Member

Society for Immunotherapy in Cancer, Currently Active

Member

International Association for Study of Lung Cancer, Currently Active

Member

American Society of Clinical Oncology, -

Research Interests

Clinical trials and biological correlates of disease

Publications

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multi-center randomized phase 3 trial

Nature Medicine – Professor Hai-Qiang Mai , Dr Qiuyan Chen , Dr Dongping Chen , Chaosu Hu , Dr Kunyu Yang , Dr Jiyu Wen , Dr Jingao Li , Dr Yingrui Shi , Dr Feng Jin , Dr Ruilian Xu , Dr Jianji Pan , Dr Shenhong Qu , Dr Ping Li , Dr Chunhong Hu , Dr Yi-Chun Liu , Dr Yi Jiang , Dr Xia He , Dr Hung-Ming Wang , Dr Wan-Teck Lim , Dr Wangjun Liao , Dr Xiaohui He , Dr Xiaozhong Chen , Dr Zhigang Liu , Dr Xianglin Yuan , Dr Qi Li , Dr Xiaoyan Lin , Dr Shanghua Jing , Dr Yanju Chen , Dr Yin Lu , Dr Ching-Yun Hsieh , Professor Muh-Hwa Yang , Dr Chia-Jui Yen , Dr Jens Samol , Dr Hui Feng , Dr Sheng Yao , Dr Patricia Keegan (2021)

27 (9); 1536-1543

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer

Clinical Cancer Research – C. Even, H-M. Wang, S-H. Li, R. Ngan, A. Dechaphunkul, L. Zhang, C. J. Yen, P. C. Chan, S. Chakrabandhu, B. Ma, S. Tanasanvimon, V. Lee, P-J. Lou, Z. Li, A. Spira, A. Sukari, J. Guigay, S. McCune, J. Gonzalez-Maffe, S. Szpakowski, Y. Yao, H. Liang, J. Mataraza, R. Séchaud, L. Manenti, D. W-T. Lim (2021)

27 (23); 6413-6423

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology – Ma Brigette B Y; Lim Wan-Teck; Goh Boon-Cher; Hui Edwin P; Lo Kwok-Wai; Pettinger Adam; Foster Nathan R; Riess Jonathan W; Agulnik Mark; Chang Alex Y C; Chopra Akhil; Kish Julie A; Chung Christine H; Adkins Douglas R; Cullen Kevin J; Gitlitz Barbara J; Lim Dean W; To Ka-Fai; Chan K C Allen; Lo Y M Dennis; King Ann D; Erlichman Charles; Yin Jun; Costello Brian A; Chan Anthony T C (2018)

36 (14); 1412-1418

Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing immunotherapy

Cancers – Wai Nam Liu, Shin Yie Fong, Wilson Wei Sheng Tan, Sue Yee Tan, Min Liu, Jia Ying Cheng, Sherily Lim, Lisda Sutedja, Edwin Kunxiang Huang, Jerry Kok Yen Chan, Narayanan Gopalakrishna Iyer, Joe Poh Sheng Yong, Darren Wan-Teck Lim, Qingfeng Chen. (2020)

12 (4);

A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research – Lim Wan-Teck; Ng Quan-Sing; Ivy Percy; Leong Swan-Swan; Singh Onkar; Chowbay Balram; Gao Fei; Thng Choon Hua; Goh Boon-Cher; Tan Daniel Shao-Weng; Koh Tong San; Toh Chee-Keong; Tan Eng-Huat (2011)

17 (16); 5481-9

International consensus recommendations on measuring plasma EBV DNA in managing nasopharyngeal carcinoma in the setting of acute severe manpower and resource constraint during COVID pandemic

Lancet Oncology – VHF Lee, M Adham, WB Kridis, P Bossi, MY Chen, I Chitaparanux, V Gregoire, SP Hao, C Ho, GF Ho, D Kannarunimit, DLW Kwong, KO Lam, WKJ Lam, QT Le, AWM Lee, NY Lee, TW Leung, L Licitra, DWT Lim, JC Lin, KS Loh, PJ Lou, JP Machiels, HQ Mai, R Mesia, WT Ng, RKC Ngan, JK Tay, RKY Tsang, CC Tong, HM Wang, J Wee (2022)

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Nature medicine – Ng King Pan; Hillmer Axel M; Chuah Charles T H; Juan Wen Chun; Ko Tun Kiat; Teo Audrey S M; Ariyaratne Pramila N; Takahashi Naoto; Sawada Kenichi; Fei Yao; Soh Sheila; Lee Wah Heng; Huang John W J; Allen John C; Woo Xing Yi; Nagarajan Niranjan; Kumar Vikrant; Thalamuthu Anbupalam; Poh Wan Ting; Ang Ai Leen; Mya Hae Tha; How Gee Fung; Yang Li Yi; Koh Liang Piu; Chowbay Balram; Chang Chia-Tien; Nadarajan Veera S; Chng Wee Joo; Than Hein; Lim Lay Cheng; Goh Yeow Tee; Zhang Shenli; Poh Dianne; Tan Patrick; Seet Ju-Ee; Ang Mei-Kim; Chau Noan-Minh; Ng Quan-Sing; Tan Daniel S W; Soda Manabu; Isobe Kazutoshi; Nöthen Markus M; Wong Tien Y; Shahab Atif; Ruan Xiaoan; Cacheux-Rataboul Valère; Sung Wing-Kin; Tan Eng Huat; Yatabe Yasushi; Mano Hiroyuki; Soo Ross A; Chin Tan Min; Lim Wan-Teck; Ruan Yijun; Ong S Tiong (2012)

18 (4); 521-8

Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model

Science Advances – Simon Wai-Nam Lim, Wing Yan So, Sarah L Harden, Shin Yie Fong, Melissa Xin Yu Wong, Wilson Wei Sheng Tan, Sue Yee Tan, Jessica Kai Lin Ong, Ravisankar Rajarethinam, Min Liu, Jia YIng Cheng, Lisda Sutedja, Joe Poh Sheng Yong, N Gopalakrishna Iyer, Darren Wan-Teck Lim*, Qingfeng Chen* (co-corresponding" (2022)

N.A

An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer

Nature Communications – Su Bin Lim, Swee Jin Tan, Wan-Teck Lim, Chwee Teck Lim (2017)

8 (1);

Addressing cellular heterogeneity in tumor and circulation for refined prognostication.

Proceedings of the National Academy of Sciences of the United States of America – Lim Su Bin; Yeo Trifanny; Lee Wen Di; Bhagat Ali Asgar S; Tan Swee Jin; Tan Daniel Shao Weng; Lim Wan-Teck; Lim Chwee Teck (2019)

116 (36); 17957-17962

Directory

Bio

Education

Bachelor of Medicine, Bachelor of Surgery

NUS Appointment(s)

Clinical Senior Lecturer

Academic Contribution(s)

National Day Long Service Award

Clinician Scientist Award

Outstanding Clinician Researcher

Clinician Scientist Award

Excellent Service Award (Gold)

Excellent Service Award (Silver)

Health Manpower Development Plan (HMDP) Award, SingHealth, 2004-2005

Professional Appointment(s)

Senior Consultant, Division of Medical Oncology

Director

Regular/Associate Professor

Research Director, Division of Medical Oncology

Senior Principal Investigator

Research Director

Membership

Fellow

Member

Member

Member

Member

Member

Member

Research Interests

Publications

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multi-center randomized phase 3 trial

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer

Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).

Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing immunotherapy

A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma.

International consensus recommendations on measuring plasma EBV DNA in managing nasopharyngeal carcinoma in the setting of acute severe manpower and resource constraint during COVID pandemic

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Successful targeting of PD-1/PD-L1 with chimeric antigen receptor-natural killer cells and nivolumab in a humanized mouse cancer model

An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer

Addressing cellular heterogeneity in tumor and circulation for refined prognostication.

Browser not supported

Modern websites need modern browsers